AC Immune Wins Prestigious Award to Develop a “Game-Changing” Parkinson’s Diagnostic Tool
AC Immune is one of three winners sharing USD 10 million through The Michael J. Fox Foundation Ken Griffin Alpha-synuclein Imaging Competition
The award follows compelling preclinical results presented at AAIC on the Company’s alpha-synuclein positron emission tomography -(PET) tracer program
Further validates the ability of AC Immune’s proprietary platforms to accelerate delivery of a new class of promising diagnostics in neurodegenerative diseases
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it is one of the winners of the Ken Griffin Alpha-synuclein Imaging Competition from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), and is eligible to receive together with its partner USD 3.2 million (CHF 3.1 million).